These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 31352829)

  • 1. Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial.
    Park S; Bergmark BA; Shi M; Lanz HJ; Chung N; Ruff CT; Antman EM; Braunwald E; Giugliano RP
    Hypertension; 2019 Sep; 74(3):597-605. PubMed ID: 31352829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
    Rost NS; Giugliano RP; Ruff CT; Murphy SA; Crompton AE; Norden AD; Silverman S; Singhal AB; Nicolau JC; SomaRaju B; Mercuri MF; Antman EM; Braunwald E;
    Stroke; 2016 Aug; 47(8):2075-82. PubMed ID: 27387994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 Trial.
    Fanola CL; Ruff CT; Murphy SA; Jin J; Duggal A; Babilonia NA; Sritara P; Mercuri MF; Kamphuisen PW; Antman EM; Braunwald E; Giugliano RP
    J Am Heart Assoc; 2018 Aug; 7(16):e008987. PubMed ID: 30369307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.
    Magnani G; Giugliano RP; Ruff CT; Murphy SA; Nordio F; Metra M; Moccetti T; Mitrovic V; Shi M; Mercuri M; Antman EM; Braunwald E
    Eur J Heart Fail; 2016 Sep; 18(9):1153-61. PubMed ID: 27349698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial.
    Bergmark BA; Kamphuisen PW; Wiviott SD; Ruff CT; Antman EM; Nordio F; Kuder JF; Mercuri MF; Lanz HJ; Braunwald E; Giugliano RP
    Circulation; 2019 Nov; 140(22):1792-1801. PubMed ID: 31597460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
    Giugliano RP; Ruff CT; Rost NS; Silverman S; Wiviott SD; Lowe C; Deenadayalu N; Murphy SA; Grip LT; Betcher JM; Duggal A; Dave J; Shi M; Mercuri M; Antman EM; Braunwald E;
    Stroke; 2014 Aug; 45(8):2372-8. PubMed ID: 24947287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease.
    Qamar A; Antman EM; Ruff CT; Nordio F; Murphy SA; Grip LT; Greenberger NJ; Yin OQP; Choi Y; Lanz HJ; Mercuri MF; Braunwald E; Giugliano RP
    J Am Coll Cardiol; 2019 Jul; 74(2):179-189. PubMed ID: 31296289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.
    De Caterina R; Renda G; Carnicelli AP; Nordio F; Trevisan M; Mercuri MF; Ruff CT; Antman EM; Braunwald E; Giugliano RP
    J Am Coll Cardiol; 2017 Mar; 69(11):1372-1382. PubMed ID: 28302288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
    Zelniker TA; Ardissino M; Andreotti F; O'Donoghue ML; Yin O; Park JG; Murphy SA; Ruff CT; Lanz HJ; Antman EM; Braunwald E; Giugliano RP; Merlini PA
    Circulation; 2021 Feb; 143(7):673-684. PubMed ID: 33587659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of the Win Ratio Method in the ENGAGE AF-TIMI 48 Trial Comparing Edoxaban With Warfarin in Patients With Atrial Fibrillation.
    Bergmark BA; Park JG; Hamershock RA; Melloni GEM; De Caterina R; Antman EM; Ruff CT; Rutman H; Mercuri MF; Lanz HJ; Braunwald E; Giugliano RP
    Circ Cardiovasc Qual Outcomes; 2024 Jul; 17(7):e010561. PubMed ID: 38828563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
    Kato ET; Giugliano RP; Ruff CT; Koretsune Y; Yamashita T; Kiss RG; Nordio F; Murphy SA; Kimura T; Jin J; Lanz H; Mercuri M; Braunwald E; Antman EM
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial.
    Boriani G; Ruff CT; Kuder JF; Shi M; Lanz HJ; Rutman H; Mercuri MF; Antman EM; Braunwald E; Giugliano RP
    Eur Heart J; 2019 May; 40(19):1541-1550. PubMed ID: 30624719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
    Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
    Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
    Ruff CT; Giugliano RP; Antman EM; Crugnale SE; Bocanegra T; Mercuri M; Hanyok J; Patel I; Shi M; Salazar D; McCabe CH; Braunwald E
    Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis.
    Steffel J; Giugliano RP; Braunwald E; Murphy SA; Mercuri M; Choi Y; Aylward P; White H; Zamorano JL; Antman EM; Ruff CT
    J Am Coll Cardiol; 2016 Sep; 68(11):1169-1178. PubMed ID: 27609678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48.
    Zelniker TA; Ruff CT; Wiviott SD; Blanc JJ; Cappato R; Nordio F; Mercuri MF; Lanz H; Antman EM; Braunwald E; Giugliano RP
    Eur Heart J Acute Cardiovasc Care; 2019 Mar; 8(2):176-185. PubMed ID: 30039978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation: The ENGAGE AF-TIMI 48 Trial.
    Corbalán R; Nicolau JC; López-Sendon J; Garcia-Castillo A; Botero R; Sotomora G; Horna M; Ruff CT; Hamershock RA; Grip LT; Antman EM; Braunwald E; Giugliano RP
    J Am Coll Cardiol; 2018 Sep; 72(13):1466-1475. PubMed ID: 30236308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.
    Eisen A; Giugliano RP; Ruff CT; Nordio F; Gogia HS; Awasty VR; Henderson DA; Mercuri MF; Rutman H; Antman EM; Braunwald E
    Am Heart J; 2016 Feb; 172():144-51. PubMed ID: 26856226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.
    Bohula EA; Giugliano RP; Ruff CT; Kuder JF; Murphy SA; Antman EM; Braunwald E
    Circulation; 2016 Jul; 134(1):24-36. PubMed ID: 27358434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 study.
    de Groot JR; Ruff CT; Murphy SA; Hamershock RA; Vehmeijer JT; Oude Ophuis AJM; Grip L; Lanz H; Mercuri MF; Antman EM; Giugliano RP
    Am Heart J; 2021 May; 235():132-139. PubMed ID: 33493453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.